The Woodlands, Texas – January 28, 2011
Dr. Bryan Byong Jin Kim (43), President and CEO of VGX International (“VGXI”), was named as “The Most Powerful Business Leaders in Korea” in the “Biotechnology Enterprise Sector” by Fortune Korea that was held at the Millennium Hilton Hotel on December 23rd, 2010.
The award citation highlighted Dr. Kim’s contribution for positioning VGXI as a leading biotechnology company in DNA vaccine development and manufacturing in Asia region. He was also acknowledged for successfully investing in and developing DNA vaccines, considered as a next generation in vaccine field as well as further more, for successfully building and developing a CMO (Contract Manufacturing Organization) business that specializes only in the DNA vaccine manufacturing.
Dr. Kim stated, “I am delighted that all the efforts, creativity and determination of everyone at VGXI have been recognized through a renowned organization. I find this award to be an encouragement for VGXI’s future potential rather than for any end result. Above all, I would like to put a considerable meaning in gaining recognition for VGXI’s position as a leader in DNA vaccine filed.”
According to BCC report, the global DNA vaccine market is estimated to grow 70% CAGR, achieving $2.7 billion from approximately $2 million in 2009. From here, VGX International is the leader in DNA vaccine technology, which will give market dominance advantage later in the commercialization stage.
Dr. Kim said, “It is interesting to note that VGXI has all the essential technologies to commercialize DNA vaccines; DNA vaccine design, DNA vaccine delivery device, and the plasmid DNA manufacturing. VGXI forms one consortium by working with Inovio, an affiliate of VGXI and a global leader in the development of therapeutic and prophylactic DNA vaccines and VGXI, Inc., an wholly-owned subsidiary CMO of VGX International that has proprietary manufacturing technologies in producing high-quality plasmid DNAs.” He emphasized that, “This collaboration structure with affiliates is a core competency of VGXI that distinguishes from other competitors.”
Along with Dr. Kim, 40 other people were honored as “The Most Powerful Business Leaders in Korea.”
‘Fortune Korea’, a Korean version of the renowned global business magazine ‘Fortune’ announces ‘The Most Powerful Business Leaders in Korea’ by searching for leaders from various fields. This year, selected companies and CEOs represent 12 sectors such as value management, moral management, innovative management, BT management, R&D management, and human resource management. The selection was based on the business philosophy and vision of the CEO, concrete business performance and future investments, foreign communication and collaboration structure, and economical/technological outcomes and contribution in the last 3 years.
About VGXI Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies’ clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset. For information, visit 18.104.22.168/~vgxiico2
Factors That May Affect Future Results
Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations.Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.